OPKO HEALTH, INC. 8K

OPKO Health, Inc. announced its second quarter 2026 financial results and business updates, highlighting progress in multiple clinical programs, an expanded Nicoya commercialization agreement for RAYALDEE in Greater China, stronger IP and partnership revenue, improved operating results, and updated financial guidance, to be discussed on a July 27, 2026 conference call.

On July 27, 2026, OPKO Health, Inc. reported its business highlights and financial results for the quarter ended June 30, 2026, detailing progress across multiple clinical programs, an expanded commercialization agreement, and improved financial performance. The company’s ModeX subsidiary advanced its multispecific antibody-targeted in vivo CAR T platform toward planned Phase 1 studies in autoimmune disease, initiated Phase 1 trials for MDX2003 in relapsed/refractory B-cell lymphoma and MDX2301 for prevention of COVID-19 (the latter funded by BARDA), and continued Phase 1 enrollment for MDX2001 and MDX2004 with initial data expected in the first half of 2027. OPKO also began a Phase 1/2a study of OPK-88006, a dual GLP-1/glucagon agonist for presumed MASH, and presented preclinical data on long-acting growth hormone receptor antagonist OPK8801001, which it plans to move into clinical trials by year-end 2026. In collaboration with Entera Bio, OPKO highlighted preclinical progress on EB612 and EB618 and noted Entera Bio’s oversubscribed $275 million private placement supporting these programs. Commercially, OPKO amended and expanded its Nicoya agreement for RAYALDEE commercialization in Greater China, receiving a 15% equity stake in Nicoya and recognizing $29.4 million of revenue from shares issued under the amended license while retaining up to $115 million in potential milestones. Financially, OPKO reported second quarter 2026 revenues of $163.5 million (up from $156.8 million in 2025), a significantly improved operating loss of $7.0 million (versus $60.0 million), and a narrowed net loss of $8.4 million or $0.01 per share (versus $148.4 million or $0.19 per share), driven largely by higher intellectual property and partnership revenue and the absence of prior-year oncology operations sold to Labcorp, while maintaining cash, cash equivalents, marketable securities and restricted cash of $314.4 million and continuing share repurchases under its authorization. The company also provided quantitative revenue and cost guidance for the third quarter and full year 2026 and announced a same-day conference call and webcast to discuss these results and outlook.

Filing Facts

CIK

944809

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-318069

Alert Tier

7